NAB815 

NAB815 is a specific inhibitor of the Stx2a (K_d = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC₅₀ = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS)^[1][2].

NAB815 (1 nM, 4 h) inhibits the formation of white blood cell/platelet aggregates by Stx2a^[1].
NAB815 (0.01-0.1 μg/mL, 4 h) slightly affects the viability of human leukocytes but has no effect on erythrocytes, inhibits the formation of platelet-derived and leukocyte-derived pathogenic EVs containing Stx2a, impairs the recruitment of complement factors in Stx2-induced EVs^[1].
NAB815 (0.01 μg/mL) affords protection against toxicity induced by Stx2a-triggered EVs in Vero cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NAB815 (0.01 μg/mL, 100 μL, i.v., once) affords protection against free Stx2a in CD-1 mice^[1].
NAB815 (0.01 μg/mL, 300 μL, i.v., once) affords protection against EV-associated Stx2a in Human EVs CD-1 mice^[1].
NAB815 (0.5-2 mg/L, 0.2 mL, s.c., twice a day, 3 days) reduces the bacterial burden in the kidney, urine and bladder in E. coli-infected female OF-1 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1175.42

C₅₅H₉₄N₁₄O₁₄

1969250-99-4

Octanoic-{Dab}-Thr-{d-Thr}-{Dab}-{Dab}-{d-Phe}-Leu-{Abu}-{Dab}-Thr (lactam bridge: Dab4-Thr10)

Octanoic-{Dab}-T-{d-Thr}-{Dab}-{Dab}-{d-Phe}-L-{Abu}-{Dab}-T (lactam bridge: Dab4-Thr10)

O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(NCC[C@@H](C(N[C@H](C(N1)=O)CCN)=O)NC([C@@H]([C@@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCCCCC)=O)=O)=O)=O)=O)([H])[C@H](O)C)=O)CCN)=O)CC)=O)CC(C)C)[C@H]1CC2=CC=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Varrone E, et al. An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome. iScience. 2025 Jul 7;28(8):113076.  [Content Brief]

  [2]. Vaara M, et al. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. J Antimicrob Chemother. 2018 Feb 1;73(2):452-455.  [Content Brief]